Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy

The present study aims to conduct a randomized controlled trial to evaluate the efficacy and safety of 3-n-Butylphthalide (NBP) in improving symptoms in patients with Multiple System Atrophy (MSA). The main questions it aims to answer are: 1. To evaluate whether NBP soft capsules, compared with placebo, alleviates the major clinical symptoms in patients with MSA. 2. Whether NBP application is safe to treat patients with MSA. In this trial, NBP will be compared with placebo (similar soft capsule without effective component of NBP) to demonstrate if NBP can alleviates MSA symptoms Participants of ENMSA will: 1. Take NBP or Placebo three times a day for 6 months 2. Be served with clinical visit four times for follow-up and tests 3. Keep a diary of drug application and symptom changes

NCT Number	NCT07518810
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University Collaborators: The Second Affiliated Hospital of Jiaxing University, Beijing Chao Yang Hospital, Huzhou Central Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, First Affiliated Hospital of Guangxi Medical University, Ningbo No.2 Hospital
Conditions	Multiple System Atrophy
Enrollment	150 participants
Start Date	2026-04-10
Primary Completion	2027-04-10 (estimated)
Study Completion	2027-10-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-09